What is the current price and market cap of AYA.AX stock?

AYA.AX stock closed at **A$2.70** on 24 Mar 2026. Market cap is **A$298,156,000.00** with **113,800,000.00** shares outstanding on the ASX in Australia.

What are Meyka AI's forecast and price targets for AYA.AX stock?

Meyka AI's forecast model projects **Monthly A$3.05**, **Quarterly A$4.36** and **12‑month A$7.41** for the AYA.AX stock. These imply 12.96%, 61.48% and 174.36% upside respectively versus A$2.70. Forecasts are model-based projections and not guarantees.

What are the main risks for AYA.AX stock investors?

Main risks for AYA.AX stock include continued negative earnings (EPS **-0.17**), high R&D expense concentration, slow hospital adoption cycles, and possible future capital raises that could dilute shareholders.

How does AYA.AX stock compare with healthcare peers on valuation?

AYA.AX stock has a price-to-book of **3.69**, near the sector average PB **3.97**, but it reports negative earnings. Compared with profitable peers, Artrya is a high‑growth, high‑risk AI healthcare play.

AU Stocks

AYA.AX Artrya Limited ASX A$2.70 (Market Closed 24 Mar 2026): AI stock outlook

ByHuzaifa Zahoor March 24, 2026

Artrya Limited (AYA.AX) closed at A$2.70 on the ASX on 24 Mar 2026, a small rise from the prior close. The AYA.AX stock has moved from a 52-week low of A$0.56 to a 52-week high of A$5.24, highlighting wide swings in market sentiment. Trading volume was 608,820 shares versus an average of 524,780, keeping liquidity adequate for ASX mid-caps. This piece examines the AYA.AX stock fundamentals, technicals, Meyka AI grade and near-term price forecasts for investors focused on AI healthcare plays.